Literature DB >> 12865067

Distinct immune profiles characterize patients with diffuse or limited systemic sclerosis.

Francesca Ingegnoli1, Daria Trabattoni, Marina Saresella, Flavio Fantini, Mario Clerici.   

Abstract

Mitogen-stimulated IL-2, IFN-gamma, TNF-alpha (type 1 cytokines), and IL-10 (type 2 cytokine) production by peripheral blood mononuclear cells, as well as expression of surface markers on immune cells, was evaluated in systemic sclerosis (SSc) patients. Fifty-four SSc patients with either diffuse (dSSc) or limited (lSSc) disease and 20 age- and sex-matched healthy controls (HCs) were examined. Fourteen patients were treated with prednisone and 9 patients with prednisone and cyclophosphamide pulses. Results showed that (1) IL-2 production is significantly decreased, whereas IL-10 is higher in untreated patients compared to HCs; IL-10, IFN-gamma, and TNF-alpha production is higher in lSSc compared to dSSc patients; (2) CD4+25+ (IL-2R), CD8+, and CD8+45RA-28+57- (memory) lymphocytes are reduced in patients compared to HCs; (3) CD95-expressing CD4+ and CD8+ cells are significantly higher in dSSc patients; and (4) steroids are more effective alone than in combination with cyclophosphamide in reducing IL-10 and IFN-gamma production in these patients. These results confirm that a complex imbalance in cytokine production is present in SSc patients and suggest that peculiar phenotypic populations are underrepresented in these patients. Overexpression of Fas in dSSc could results from the attempt of the immune system to induce apoptosis of autoreactive T-cell clones.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865067     DOI: 10.1016/s1521-6616(03)00062-7

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  10 in total

1.  Linking new and old concepts: inflammation meets the Warburg phenomenon in pulmonary arterial hypertension.

Authors:  Todd M Kolb; Rachel L Damico; Paul M Hassoun
Journal:  J Mol Med (Berl)       Date:  2011-08       Impact factor: 4.599

Review 2.  Could Lymphocyte Profiling be Useful to Diagnose Systemic Autoimmune Diseases?

Authors:  Guillermo Carvajal Alegria; Pierre Gazeau; Sophie Hillion; Claire I Daïen; Divi Y K Cornec
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

Review 3.  The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension.

Authors:  Nada Kherbeck; Mathieu C Tamby; Guillaume Bussone; Hanadi Dib; Frederic Perros; Marc Humbert; Luc Mouthon
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 4.  Challenges and opportunities in treating inflammation associated with pulmonary hypertension.

Authors:  Norbert F Voelkel; Rasa Tamosiuniene; Mark R Nicolls
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-05-04

Review 5.  T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review.

Authors:  Isabel Almeida; Sara Vieira Silva; Ana Raquel Fonseca; Ivone Silva; Carlos Vasconcelos; Margarida Lima
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

6.  Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling.

Authors:  Laimute Taraseviciene-Stewart; Mark R Nicolls; Donatas Kraskauskas; Robertas Scerbavicius; Nana Burns; Carlyne Cool; Kathy Wood; Jane E Parr; Susan A Boackle; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2007-04-05       Impact factor: 21.405

7.  Dynamics of the human antibody repertoire after B cell depletion in systemic sclerosis.

Authors:  Charles F A de Bourcy; Cornelia L Dekker; Mark M Davis; Mark R Nicolls; Stephen R Quake
Journal:  Sci Immunol       Date:  2017-09-29

8.  Absolute count of T and B lymphocyte subsets is decreased in systemic sclerosis.

Authors:  Thilo Gambichler; C Tigges; B Burkert; S Höxtermann; P Altmeyer; A Kreuter
Journal:  Eur J Med Res       Date:  2010-01-29       Impact factor: 2.175

Review 9.  Current perspective on rituximab in rheumatic diseases.

Authors:  Tommaso Schioppo; Francesca Ingegnoli
Journal:  Drug Des Devel Ther       Date:  2017-10-03       Impact factor: 4.162

10.  Natural Killer Cells Exhibit a Peculiar Phenotypic Profile in Systemic Sclerosis and Are Potent Inducers of Endothelial Microparticles Release.

Authors:  Audrey Benyamine; Jérémy Magalon; Florence Sabatier; Luc Lyonnet; Stéphane Robert; Chloé Dumoulin; Sophie Morange; Karin Mazodier; Gilles Kaplanski; Martine Reynaud-Gaubert; Pascal Rossi; Françoise Dignat-George; Brigitte Granel; Pascale Paul
Journal:  Front Immunol       Date:  2018-07-18       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.